Abstract: A polypeptide having superoxide dismutase (SOD) activity and/or extracellular vesicles containing SOD is effective for the prevention and/or treatment of respiratory viral infection or diseases caused by respiratory viral infection in a subject. The polypeptide has SOD activity derived from a Bacillus amyloliquefaciens strain and/or extracellular vesicles containing SOD derived from a Bacillus subtillis strain is useful for the prevention and/or treatment of respiratory viral infection or diseases caused by respiratory viral infection in a subject.
Type:
Application
Filed:
November 23, 2021
Publication date:
January 4, 2024
Applicant:
GENOFOCUS CO., LTD.
Inventors:
Jae Gu PAN, Eui Joong KIM, Jeong Hyun KIM
Abstract: The present invention relates to a beta-galactosidase mutant having high transglycosylation activity and containing a C-terminal deletion, and the use thereof and more. More specifically, the present invention relates to a beta-galactosidase mutant having a C-terminal deletion, a gene encoding the same, a recombinant vector containing the gene, a recombinant microorganism transformed with the gene or the recombinant vector, and a method for producing the beta-galactosidase mutant using the recombinant microorganism. Using the high transglycosylation activity of the beta-galactosidase mutant containing the C-terminal deletion according to the present invention, galactooligosaccharide can be efficiently produced in large amounts.
Type:
Grant
Filed:
May 19, 2016
Date of Patent:
January 7, 2020
Assignee:
GENOFOCUS CO., LTD.
Inventors:
Su Jin Kim, Young-Jae Eu, Taek Ho Yang, Jae Gu Pan, Eui Joong Kim
Abstract: The present invention relates to a novel alpha-1,3-glucanase, and more particularly, to a novel alpha-1,3-glucanase from Trichoderma harzianum, a gene encoding the same, a recombinant vector and recombinant microorganism comprising the gene, and a method of producing an alpha-1,3-glucanase using the recombinant microorganism. The novel alpha-1,3-glucanase according to the present invention can effectively degrade mutan, which is a component of a microbial biofilm, and thus it can be used in oral hygiene products and the medical field.
Type:
Grant
Filed:
July 15, 2016
Date of Patent:
November 12, 2019
Assignee:
GENOFOCUS CO., LTD.
Inventors:
Jae Gu Pan, Eui Joong Kim, Taek Ho Yang, Dong Beom Lee, Eun Young Kim, Hye Rim Lee, Jung Hyun Kang
Abstract: The present invention relates to a novel beta-galactosidase, and more particularly to a novel beta-galactosidase derived from Bacillus circulans, a gene encoding the beta-galactosidase, a recombinant vector and a recombinant microorganism, which contain the gene, a method for producing a beta-galactosidase using the recombinant microorganism, and a method for producing galactooligosaccharide using the beta-galactosidase. The use of the novel beta-galactosidase according to the present invention makes it possible to efficiently produce a large amount of galactooligosaccharide.
Type:
Grant
Filed:
May 19, 2015
Date of Patent:
July 31, 2018
Assignee:
GENOFOCUS CO., LTD.
Inventors:
Jae Youl Choi, Jae Gu Pan, Seung Hwan Park, Eui Joong Kim
Abstract: The present invention relates to a beta-galactosidase mutant having high transglycosylation activity and containing a C-terminal deletion, and the use thereof and more. More specifically, the present invention relates to a beta-galactosidase mutant having a C-terminal deletion, a gene encoding the same, a recombinant vector containing the gene, a recombinant microorganism transformed with the gene or the recombinant vector, and a method for producing the beta-galactosidase mutant using the recombinant microorganism. Using the high transglycosylation activity of the beta-galactosidase mutant containing the C-terminal deletion according to the present invention, galactooligosaccharide can be efficiently produced in large amounts.
Type:
Application
Filed:
May 19, 2016
Publication date:
June 7, 2018
Applicant:
GENOFOCUS CO., LTD.
Inventors:
Su Jin Kim, Young-Jae Eu, Taek Ho Yang, Jae Gu Pan, Eui Joong Kim